Abstract
Introduction
Thiazolidinedione (TZD) is one of the therapy options for polycystic ovary syndrome (PCOS) patients; however, the effectiveness of TZD in the treatment of PCOS remains controversial. The aim of this metaanalysis was to clarify the role that TZDs play in the treatment of PCOS.
Methods
The authors searched the following databases for any date up to June 2012 for randomized controlled trials on PCOS treatment in which interventions for the experimental and control groups were TZDs and placebo, respectively: Medline, Embase, and the Cochrane library.
Results
The search strategy identified 173 potential publications, eight of which were included. In the treatment of PCOS, the insulin-lowering effects of TZDs were superior to placebo (95% CI −1.50 to −0.12; P = 0.021), and the lowering of fasting blood glucose was superior to placebo (95% CI −1.06 to −0.05; P = 0.031). There was no difference in reduction of the Ferriman-Gallwey scores or the androgen levels between TZDs and placebo (95% CI −0.57 to 0.10; P = 0.169 and 95% CI −0.64 to 0.09; P = 0.141, respectively). The effects of TZDs on body weight reduction were inferior to placebo (95% CI 0.13 to 0.66; P = 0.003). Significant between-study heterogeneity was detected for several variables assessed.
Conclusion
This is the first meta-analysis to evaluate the role that TZDs plays in the treatment of PCOS compared with placebo. The currently available data showed that TZDs can effectively reduce insulin and fasting blood glucose levels in patients with PCOS, but TZDs may not effectively reduce the Ferriman-Gallwey score or androgen levels and may increase body weight.
Similar content being viewed by others
References
Gangale MF, Miele L, Lanzone A, et al. Longterm metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf). 2011;75:520–527.
Kim JJ, Choi YM, Cho YM, et al. Prevalence of elevated glycated hemoglobin in women with polycystic ovary syndrome. Hum Reprod. 2012;27:1439–1444.
Chang AY, Ayers C, Minhajuddin A, et al. Polycystic ovarian syndrome and subclinical atherosclerosis among women of reproductive age in the Dallas heart study. Clin Endocrinol (Oxf), 2011;75:89–96.
Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95:2038–2049.
Phelan N, O’Connor A, Kyaw-Tun T, et al. Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS. J Clin Endocrinol Metab. 2010;95:3933–3939.
Fearnley EJ, Marquart L, Spurdle AB, et al. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control. 2010;21:2303–2308.
Atiomo W, Read A, Golding M, et al. Local recruitment experience in a study comparing the effectiveness of a low glycaemic index diet with a low calorie healthy eating approach at achieving weight loss and reducing the risk of endometrial cancer in women with polycystic ovary syndrome (PCOS). Contemp Clin Trials. 2009;30:451–456.
Vgontzas AN, Bixler EO, Chrousos GP. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med. 2003;254:32–44.
Ahmed W, Ziouzenkova O, Brown J, et al. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med. 2007;262:184–198.
Koenen TB, Tack CJ, Kroese JM, et al. Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients. J Clin Endocrinol Metab. 2009;94:4453–4457.
Schoppee PD, Garmey JC, Veldhuis JD. Putative activation of the peroxisome proliferator-activated receptor γ impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells. Biol Reprod. 2002;66:190–198.
Faich GA, Moseley RH. Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Saf. 2001;10:537–547.
Bell DS, Ovalle F. Late-onset troglitazone-induced hepatic dysfunction. Diabetes Care. 2000;23:128–129.
Murphy EJ, Davern TJ, Shakil AO, et al. Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. Dig Dis Sci. 2000;45:549–553.
Li XJ, Yu YX, Liu CQ, et al. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. Clin Endocrinol (Oxf). 2011;74:332–339.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, ed. Polycystic Ovary Syndrome. Boston: Blackwell Scientific, 1995:377–384.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;21:339.
DerSimonian R, Kacker, R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105–114.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
Naka KK, Kalantaridou SN, Kravariti M, et al. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril. 2011;95:203–209.
Aigner E, Bachofner N, Klein K, et al. Retinolbinding protein 4 in polycystic ovary syndrome—association with steroid hormones and response to pioglitazone treatment. J Clin Endocrinol Metab. 2009;94:1229–1235.
Aroda VR, Ciaraldi TP, Burke P, et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2009;94:469–476.
Glintborg D, Hermann AP, Andersen M, et al. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertil Steril. 2006;86:385–397.
Ma LK, Jin LN, Yu Q, Xu L. Effect of lifestyle adjustment, metformin and rosiglitazone in polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi. 2007;42:294–297.
Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod. 2006;21:1400–1407.
Baillargeon JP, Jakubowicz DJ, Iuorno MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril. 2004;82:893–902.
Liao L, Tian YJ, Zhao JJ, et al. Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. Chin Med J (Engl). 2011;124:714–718.
Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–1447.
Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment assignment in controlled clinical trials. N Engl J Med. 1983;309:1359–1361.
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–412.
Cochrane Handbook for Systematic Reviews of Interventions. Available at: External link http://www.cochrane-handbook.org/. Accessed June 22 2012.
Bloomgarden ZT. Type 2 diabetes: uses of thiazolidinediones and insulin. Diabetes Care. 2011;34:11–16.
Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status. Adv Ther. 2009;26:893–907.
Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE. Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol. 2008;153:636–645.
Ko GT, Tsang PC, Wai HP, et al. Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: a 1-year randomized clinical trial. Adv Ther. 2006;23:799–808.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;14:2457–2471.
Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta. 2007;1771:1065–1081.
Nissen SE, Wolski K. Rosiglitazone Revisited: An updated meta-analysis of risk in for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191–1201.
Singh S, Loke Y.K, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a metaanalysis. JAMA. 2007;298:1189–1195.
Bodmer M., Meier C, Kraenzlin ME, Meier CR. Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf. 2009;32:539–547.
Piccinni C, Motola D, Marchesini G, et al. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34:1369–1371.
Lewis JD, Ferrara A, Peng T, Poluzzi E. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34:916–922.
Li W, Macdonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol. 2012. Epub ahead of print.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Du, Q., Yang, S., Wang, YJ. et al. Effects of Thiazolidinediones on Polycystic Ovary Syndrome: a Meta-analysis of Randomized Placebo-Controlled Trials. Adv Therapy 29, 763–774 (2012). https://doi.org/10.1007/s12325-012-0044-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-012-0044-6